$Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy$
QR Code

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy, who progressed and received a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, Lucia Esposito, Nicola Normanno, Antonio Avallone, Tiziana Latiano, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Giuseppe Santabarbara, Carmine Pinto, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Format:	article
Language:	EN
Published:	MDPI AG 2021
Subjects:	rechallenge anti-EGFR immunotherapy skin toxicity mCRC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/644e2914914c48e9b39e0f6cb9eac8c7
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

Similar Items